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Abstract 
 
A genetic basis for autism spectrum disorder (ASD) is new well established, and with the 
availability of high-throughput microarray and sequencing platforms major advances have 
been made in our understanding of genetic risk factors. Rare, often de novo, copy number and 
single nucleotide variants are both implicated, with many  ASD-implicated genes showing 
pleiotropy and variable penetrance. Additionally, common variants are also known to play a 
role in ASD’s genetic etiology, but are yet to be identified. These new insights into the 
architecture of ASD’s genetic etiology offer opportunities for the identification of molecular 
targets for novel interventions, and provide new insight for families seeking genetic 
counselling.  
 
 
 
 
Shortened title: Progress in genetics of ASD 
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What the paper adds 
 
 A number of rare, often de novo, genetic variants, including deletions and 
duplications, are implicated in ASD, with some showing recurrence. 
 
 Common genetic variants are also important and a number of associated loci are now 
being uncovered. 
 
 Genetic testing for individuals diagnosed with ASD can offer the opportunity to 
identify relevant genetic etiology, thus facilitating counselling. 
 
Introduction 
 
Autism Spectrum Disorder (ASD) is a childhood onset lifelong disorder that impacts socio-
communicative development and is also characterized by rigidity and ritualistic/repetitive 
patterns of behaviour. It occurs with a population prevalence of ~1%, with a male 
preponderance of 4:1. 1 In approximately 50% of cases there is an association with 
intellectual disability (ID), and co-morbidity with neurodevelopmental and psychiatric 
disorders is frequent. 1 In some cases, ASD forms part of a syndrome, usually in association 
with known single gene disorders. 2 ASD can occur sporadically, but is often familial, with a 
sibling recurrence risk in the region of 10-20 times. 3 Recognising these varied phenotypic 
manifestations, it is unsurprising that the underlying etiological architecture of ASD is also 
complex; it is widely accepted, however, that genetic factors play a crucial role, and that both 
common and rare forms of genetic variation confer susceptibility.  
 
With the availability of affordable, high throughput microarray and whole genome 
sequencing (WGS) platforms (Figure 1), the spectrum of population based human genetic 
variation is now more fully understood. Individuals harbour in the region of 3 million genetic 
variants, 95% of which are shared with >5% of the population and are termed ‘common 
variants’, 4% shared with between 1-4% of the population, and 1% of which are rare or 
unique to any one individual or their immediate family. 4 Some such variants are de novo, i.e. 
arise in the germline. This distinction between common and rare variation provides a useful 
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categorization for understanding the genetic architecture of many complex genetic disorders, 
including ASD. Specifically, the liability to ASD is now known to involve both rare variants 
of moderate effect size, and common variants, individually of small effect size but 
cumulatively conferring susceptibility above a theoretical level of liability. 4 As discussed 
subsequently, much is known about the ‘rare’ end of the allelic spectrum of ASD’s etiology, 
with both de novo and rare inherited variants and complex structural rearrangements 
identified in both sporadic and inherited forms of the disorder. 2 In contrast, although 
common variation is now known to be etiologically important, 5 no replicated variants have 
yet been identified.  
 
Figure 1 about here 
 
 
Rare mutations in ASD 
 
Single gene disorders: the identification of rare de novo and inherited genetic variants that 
are predicted damaging represents the most successful aspect of ASD gene discovery. Among 
some individuals, these risk variants form part of known genetic syndromes.  Certain 
Mendelian genetic disorders are strongly associated with ASD, most notably Rett syndrome, 
among whom 40% are diagnosed with ASD, as well as Fragile X syndrome which is 
associated with ASD (25%) as well as other social phenotypes (e.g. social anxiety in >40%). 
Many other single gene disorders are also associated with ASD, including neurofibromatosis, 
tuberous sclerosis, and Williams-Beuren syndrome. All of these disorders are also associated 
with intellectual disability, and many with other neuropsychiatric disorders. Although 
individually these disorders are rare, cumulatively they account for approximately 10% of all 
cases of ASD. 2 Routine screening for Rett syndrome and Fragile X syndrome among 
individuals with ASD has been established practice for several years, but clinicians should be 
alert to the possibility of other single gene disorders that may occur sporadically.  
 
Copy number variation: with the availability of microarray platforms, offering higher 
resolution high-throughput genome scanning, duplication or deletion of segments of the 
genome have been described among individuals with ASD (Figure 1). These range in size 
from cytogenetically visible rearrangements to regions of copy number variation (typically 
involving more than 1kb) and smaller regions of insertion and deletion (indels, typically up to 
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~1kb in length). Microarray studies largely converge on evidence for a greater burden for de 
novo mutations (both deletions and duplications) in ASD families compared with controls, 
with the proportion of de novo copy number variants (CNVs) three to five-fold higher in 
cases. 6, 7 Moreover, there is a higher mutational burden for large CNVs among ASD cases 
compared to non-ASD controls, as well as CNVs that overlap (i) known ID and/or ASD 
genes, (ii) pathogenic or otherwise clinically relevant genes, and (iii) genes that are brain 
expressed and more specifically those that are structurally and/or functionally related to the 
post-synaptic density (PSD) or chromatin remodelling/transcription regulation gene sets. 6-8  
At least 5% of individuals with ASD are carrying two or more penetrant mutations. 9 
 
Several rare recurrent, de novo exonic CNVs overlap genes that are promising candidates for 
ASD susceptibility, including NRXN1, 10 PTCHD1, 11 NLGN1 genes 12 and SHANK 1 and 3. 
13, 14  Certain loci are recurrently found to be duplicated or deleted in ASD, including 16p11.2 
(~0.8%), 15-17 15q11-13 (~0.5%) 18 and 22q11 (~0.5%). 19. Mutations in these genes and loci 
are also observed in the general population (Table 1, and see knowledge translation below). 
Other similar loci have been described, comprising small and large loci of CNV loss or gain. 
These loci are often pleiotropic and overlap DECIPHER genes listed in DECIPHER, a web-
based platform for the sharing of plausibly pathogenic variants from well-phenotyped 
patients. They also as well as sshowing a similar association with other neuropsychiatric 
disorders. Although rare in the population, variants overlapping these regions are sometimes 
transmitted from parents who are without apparent phenotypic consequence. 9  For example, 
exonic CNV deletions overlapping NRXN1 at 2p16.3 have been described in 0.11% of 
clinically ascertained samples (0.11%), but are also seen in 0.02% of population controls. 10  
It is therefore important to consider the penetrance of such mutations when attempting to 
counsel families on risk. 20. Additionally, smaller maternally inherited duplications enriched 
for CHD8 gene targets show a bias in transmission to ASD probands. It is possible that this 
class of inherited CNV of reduced penetrance (and SNV, see below) simply predisposes an 
individual to ASD, requiring additional factors (genetic or otherwise) to cause the clinical 
phenotype. 21  
 
  Table 1 about here 
 
Single nucleotide variation (SNV): several large-scale sequencing projects have now been 
completed, including those that examine the entire coding region of the genome (whole 
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exome sequencing) 22 23 and the entire genome (whole genome sequencing). 9, 24, 25 Among 
simplex families, the rates of rare de novo and inherited SNVs that are predicted damaging is 
higher in ASD cases than in their unaffected siblings. 22 23 In contrast, the rate of synonymous 
mutations does not differ. Protein truncating SNVs that impact conserved genes and show 
preferential maternal transmission are enriched in ASD probands. Similar to the maternally 
transmitted CNVs discussed above, these may be low penetrance mutations that predispose to 
ASD, requiring a ‘second hit’ to cause the clinical phenotype. 21 
 
Strikingly, rates of exonic de novo mutations similar to these were also reported in a study of 
affected sib pairs; 24 while in some cases an identical ASD-implicated mutation was shared 
between affected siblings, in others each sibling harboured unique ASD-implicated 
mutations. This evidence for genetic heterogeneity both between and within families, along 
with pleiotropy, speaks to the need for precision medicine, a personalized approach to 
genetics that is cognizant of the fact that assessment of an individual’s complete genomic risk 
is required.  
 
One important finding from sequencing based studies is the relationship between paternal age 
and rates of rare, de novo variants. Specifically, the majority of point mutations in ASD 
originate from the father, with the correlation between paternal age and number of de novo 
events reflecting a 1.3-fold increase in the number of de novo events for every 10 years of 
paternal age. 26 The evidence for a relationship between de novo mutations and maternal age 
is less consistent. A similar relationship is observed for de novo events in other 
neuropsychiatric disorders such as schizophrenia. 27  
 
Common mutations in ASD 
 
Among inherited forms of ASD, it is not unusual for first or second-degree relatives to share 
milder but related characteristics, termed the broader autism phenotype (BAP). 28 In some 
cases, larger extended pedigrees show the segregation of such traits, and other 
neuropsychiatric diagnoses, more widely. 29  A genetic underpinning for the tendency for 
ASD and related traits to run in families is supported by heritability estimates. The early twin 
studies were consistent with heritability in the region of 90%, higher if lesser, subclinical 
degrees of socio-communicative and other impairments were included. 30 Although more 
recent studies have identified a larger role for shared environmental effects, 31 this is likely 
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due to the overinclusion of concordant dizygotic twins along with different liability 
thresholds used in calculations. A heritability of 64% to 91% is supported if these potential 
confounds are taken into consideration. 32  
 
Intriguingly, autism traits are normally distributed in the general population, suggesting that 
clinical ASD may represent a threshold liability with underlying common polygenic variation 
conferring susceptibility. 33 This is supported by the strong correlation between the polygenic 
contribution to ASD traits in the general population and among individuals with ASD. 34 The 
fact that many families segregating ASD also seem to share risk for other neuropsychiatric 
disorders suggests that this genetic risk may be more correctly ascribed to fundamental brain-
based traits, i.e. intermediate level phenotypes. There is a body of research examining these 
quantitative phenotypes; some have been shown to be heritable and associated with genome-
wide linkage signals in families. 35-38 In general terms, however, this has not led to gene 
discovery in ASD.  
 
Until very recently, tThe search for common variants using genome-wide association (GWA) 
methods has alsowas been largely unsuccessful. Several studies have been conducted, but in 
general terms these identifiedy signals that do not reaching a genome-wide level of 
significance. 39-41 Similarly, a recent GWA analysis of a discovery sample of 7,387 ASD 
cases failed to find individual variants that reached the genome-wide threshold; however, a 
meta-analysis with an independent sample (N=7,783 ASD cases) identified a genome-wide 
significant signal at 10q24.32 (rs1409313, OR=1.12, p=1.058e-08). 42 Although this marker 
is intronic, it is in linkage disequilibrium with a number of other markers that span a gene 
rich region. The most recent GWAS study comprising 18,381 ASD cases and 27,969 controls 
identified five genome-wide significant signals, with a further seven loci shared with other 
traits also reaching a similar level of significance. Furthermore, evidence of heterogeneity of 
association across phenotypic subgroups was observed; for example, the higher functioning 
subgroup showed an excess of alleles that overlapped with educational attainment. 43 
 
Notwithstanding the negative findings, these and other GWA studies estimate the 
contribution of common variants to ASD’s heritability to be significant. For example, the 
recent meta-analysis described above estimated SNP-based heritability to be in the region of 
32.6%. Similarly, the Swedish PAGES study (Population-based Autism Genetics and 
Environment Study) estimates heritability due to common variants to be in the region of 
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49.4%, with genetic liability spread evenly across chromosomes consistent with polygenic 
inheritance. 5 The contribution of common variation seems to be the same regardless of IQ, 
and whether or not there is a background of de novo mutations. 44 However, SNP heritability 
is higher among those cases without ID, supporting the observation that de novo and sporadic 
variants are more frequently observed among ASD cases with ID. 43 
 
Knowledge translation 
 
Interpreting results of genetic testing: One major challenge following genetic testing is the 
interpretation of results, and specifically, evidence of likely pathogenicity of identified 
variants. The American College of Medical Genetics and Genomics (ACMG) and the 
Association for Molecular Pathology (AMP) have issued joint guidelines for the 
classification of variants that uses terms ‘benign’ and ‘pathogenic’ and the strength of the 
evidence in favour of each. 45 The framework utilizes information from the population 
frequency of variants, as well as computational in silico prediction and the results of 
functional studies that consider the impact of mutation on brain structure and function in 
vitro.  In clinical terms, knowing the penetrance (i.e. the probability of a specified phenotype) 
of a particular mutation is important. The calculation of penetrance requires phenotyped 
population samples, which is often a problem considering the pleiotropy or variable 
expressivity associated with particular variants; subthreshold traits are likely to escape even 
the most detailed phenotyping. Penetrance can also be calculated by tracking inherited 
variants across family members, 46 which is a particularly useful strategy for rare variants.   
 
In general terms, although several genes are now identified as ASD genes, including NRXN1, 
SHANK 1 and 3 and PTCHD1, the penetrance of the underlying mutations is not well 
described. By way of example, deletions in NRXN1 are relatively common in clinically 
identified individuals with ASD (0.45%) and ID (0.12%), as well as in other 
neurodevelopmental phenotypes. In contrast, the frequency in population based surveys is 
much less (~0.02%). Consequently, an estimate for penetrance of NRXN1 mutations for all 
neurodevelopmental phenotypes is 33%. However, judging penetrance of conflated NRXN1 
mutations does run the risk of overstating (or understating) penetrance for individual variants. 
20 This may be problematic for genetic counsellors who are required to make judgements 
about the risk of disease for an individual. Indeed, with regards NRXN1, most clinical cases 
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seem to cluster around exons 1-4 at the 5’ end of the gene, with deletions that impact the 
subsequent exons showing evidence of lower penetrance. 47 
 
Individuals with an identical mutation may still demonstrate a large degree of phenotypic 
variability. By way of example, the 16p11.2 locus is associated with a range of 
neurodevelopmental disorders and other clinical phenotypes, including intellectual disability 
(ID). Haploinsufficiency at this locus shifts IQ downwards, but residual correlation with 
biparental IQ and ASD traits also suggest that background familial factors contribute to trait 
variability. 48 It is to be expected that a similar mechanism will explain phenotypic variation 
for other mutations. What is not entirely clear at present, however, is whether specific ASD 
symptoms are associated with particular genetic mutations. One recent analysis found that 
children with ASD who have de novo mutations had a relative strength in language but more 
pronounced motor deficits. 49 Similarly, among cases diagnosed with ASD, CNVs in 
‘ASD/ID genes’ are specifically associated with communication sub-phenotypes. 50 Much 
remains to be learned about these phenotype-genotype relationships.    
 
Providing genetic counselling for families: Genetic counsellors may be asked to advise on 
the recurrence risk of ASD among families who have one or more offspring already 
diagnosed with ASD. In families generally, the risk of having a child with ASD is related to 
the population prevalence, currently in the region of 1%. 1 Among those children deemed 
‘high-risk’ by way of an older sibling being diagnosed with ASD, 18.7% are subsequently 
diagnosed with ASD. Moreover, with two older siblings with ASD, this figure goes up to 
32.2%. 51  
 
The situation is slightly different among those families where the first child already has been 
identified as harbouring a variant overlapping an ASD gene. For recurrent CNVs, for 
example, gene-specific and/or locus-specific penetrance calculations have been generated and 
may be useful in providing genetic counselling to families, particularly as they provide 
information about penetrance for ASD and other neurodevelopmental disorders. 52 Many 
variants, however, are categorized as ‘variants of unknown significance’. In such situations, 
the variant cannot be used for clinical decision making; instead, attempts to resolve variant 
classification are needed, and the family should be monitored. A more difficult and sensitive 
situation arises when genetic testing is being used for prenatal decision making. In such 
situations, the weight given to variant classification should be aligned with the strength of the 
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evidence, and in all likelihood other factors (including additional medical investigations and 
family circumstances) will play a bigger role in the decision-making process.  
 
Assessment of an individual with ASD should include a thorough physical examination to 
document growth as well as body morphology. This may give light on the possible 
underlying genetic etiology. It is important to determine whether the individual has 
‘complex’ or ‘essential’ ASD. 53 The term ‘complex’ describes the existence of 
dysmorphology, abnormal growth, congenital anomalies and neurological complications. In 
contrast, such features are typically absent among those described as ‘essential’. Categorizing 
in this way facilitates the decision-making process in a clinical setting (Figure 2). For 
example, among individuals with head circumference >3SD from the mean the possibility of 
PTEN mutations should be considered, and developmental regression in a female patient 
should alert to the possibility of a MeCP2 mutation. For children with positive genetic test 
results, genetic counselling offers the opportunity to plan treatment and/or prophylactic 
measures for any medical conditions known to be associated with the particular gene. This 
may include close monitoring to prevent the onset of obesity in those with 16p11.2 
mutations, mental health monitoring and intervention in those with 22q11 deletions and 
cardiovascular surveillance for those with 1q21.1 microdeletion syndrome. 1  
 
 Figure 2 about here.  
 
Diagnostic yield of genetic testing: Children with developmental vulnerabilities are 
increasingly likely to have genetic testing. Among those who have ASD in association with 
dysmorphology and additional health problems, testing for Rett syndrome, Fragile X 
syndrome or one of the other single gene disorders is established practice. In recent years 
clinical microarray (CMA) has become feasible, and is increasingly used for children 
diagnosed with ASD. Indeed, a published consensus statement mandates the use of CMA as a 
first-tier diagnostic test in individuals with ID and/or ASD. 54 The diagnostic yield of such 
testing is higher than G-banded karyotyping in clinical cohorts. For example, in one study of 
848 children with ASD evaluated by CMA, 59 (7%) had results considered abnormal or 
possibly significant. Importantly, 83% of the abnormalities detected were below the size 
routinely detected by karyotyping. 55 The yield of CMA has also been compared with exome 
sequencing. 56 The yield from both were comparable (~8%), with both showing much higher 
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yield with complex ASD (21.9% vs 16.7% for CMA and exome sequencing respectively), 
defined according to the presence of dysmorphology as described in Miles et al. 57  
 
Development of molecular compounds: The identification of ASD genes, and elaboration of 
their protein pathways, offers the opportunity for the development of new molecular 
compounds that target these protein networks. Recognising that large number of genes 
identified so far, and with estimates that up to 1000 genes may be involved, 58 it is hoped that 
these converge on a relatively small number of functional protein networks that may be 
amenable to treatment, although an ‘omnigenic’ model has also been proposed. 59 A number 
of clinical trials are currently underway, principally focussing on single gene disorder causes 
of ASD, such as Rett syndrome (IGF-1), Fragile X syndrome (mGluR5 antagonists) and 
tuberous sclerosis (mTOR inhibitors). 60 The confidence that these, and other, molecular 
compounds may impact on symptoms rests on the evidence for early plasticity of the brain. 
Indeed, it has been shown, for example, that phenotypessymptoms resulting from SHANK3 
knock-out can be reversed in a mouse model in adult animals, 61 supporting potential 
therapeutic benefit during the period of plasticity and beyond. Similarly, inhibition of mTOR, 
a protein kinase, has reversed the brain changes associated with tuberous sclerosis in animal 
models, 62 and a reduction of mGLuR5 signalling has resulted in symptomatic improvement 
in knockout mice. 63  The convergence of ASD-implicated genetic variants identified so far 
on specific cellular processes, most notably several proteins involved in synaptic structure 
and function, offers the opportunity to target drug development by focussing on one or more 
distal targets of the highly interconnected pathways involved. 64  
 
Conclusion 
 
In summary, major advances have been made in recent years in our understanding of the 
genetic architecture of ASD, with strong evidence that both rare and common variants 
contribute to risk, and with recent microarray and WGS platforms providing evidence to 
support a number of genes and loci as ASD-implicated. Despite this, however, much remains 
unknown: due to the infrequent nature of individual variants, their penetrance for ASD and 
related phenotypes is not well elaborated, and functional studies are only now beginning to 
contribute to the evidence in favour of, or against, pathogenicity.  Several large-scale projects 
have now been initiated to help more fully realize the underlying complexity of ASD’s 
genetic architecture.  
 12 
 
Acknowledgements 
 
We thank The Centre for Applied Genomics (TCAG), which is funded by Genome Canada 
and the Ontario Genomics Institute, Canada Foundation for Innovation (CFI), and the Ontario 
Research Fund of the Government of Ontario. We thank the McLaughlin Centre, University 
of Toronto. S.W.S. holds the GlaxoSmithKline-CIHR Chair in Genome Sciences at the 
University of Toronto and The Hospital for Sick Children. 
 
References 
 
1. Anagnostou E, Zwaigenbaum L, Szatmari P, Fombonne E, Fernandez BA, 
Woodbury-Smith M, et al. Autism spectrum disorder: advances in evidence-based practice. 
CMAJ. 2014;186(7):509-19. 
2. Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. Curr Opin 
Genet Dev. 2012;22(3):229-37. 
3. Sandin S, Lichtenstein P, Kuja-Halkola R, Larsson H, Hultman CM, Reichenberg A. 
The familial risk of autism. JAMA. 2014;311(17):1770-7. 
4. Bourgeron T. From the genetic architecture to synaptic plasticity in autism spectrum 
disorder. Nat Rev Neurosci. 2015;16(9):551-63. 
5. Gaugler T, Klei L, Sanders SJ, Bodea CA, Goldberg AP, Lee AB, et al. Most genetic 
risk for autism resides with common variation. Nat Genet. 2014;46(8):881-5. 
6. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional 
impact of global rare copy number variation in autism spectrum disorders. Nature. 
2010;466(7304):368-72. 
7. Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, et al. Convergence 
of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet. 
2014;94(5):677-94. 
8. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, et al. Autism genome-
wide copy number variation reveals ubiquitin and neuronal genes. Nature. 
2009;459(7246):569-73. 
9. RK CY, Merico D, Bookman M, J LH, Thiruvahindrapuram B, Patel RV, et al. Whole 
genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder. 
Nat Neurosci. 2017;20(4):602-11. 
 13 
10. Dabell MP, Rosenfeld JA, Bader P, Escobar LF, El-Khechen D, Vallee SE, et al. 
Investigation of NRXN1 deletions: clinical and molecular characterization. Am J Med Genet 
A. 2013;161A(4):717-31. 
11. Noor A, Whibley A, Marshall CR, Gianakopoulos PJ, Piton A, Carson AR, et al. 
Disruption at the PTCHD1 Locus on Xp22.11 in Autism spectrum disorder and intellectual 
disability. Sci Transl Med. 2010;2(49):49ra68. 
12. Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, et al. 
Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated 
with autism. Nat Genet. 2003;34(1):27-9. 
13. Moessner R, Marshall CR, Sutcliffe JS, Skaug J, Pinto D, Vincent J, et al. 
Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet. 
2007;81(6):1289-97. 
14. Sato D, Lionel AC, Leblond CS, Prasad A, Pinto D, Walker S, et al. SHANK1 
Deletions in Males with Autism Spectrum Disorder. Am J Hum Genet. 2012;90(5):879-87. 
15. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, et al. Structural 
variation of chromosomes in autism spectrum disorder. Am J Hum Genet. 2008;82(2):477-88. 
16. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, et al. Association 
between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med. 
2008;358(7):667-75. 
17. Fernandez BA, Roberts W, Chung B, Weksberg R, Meyn S, Szatmari P, et al. 
Phenotypic spectrum associated with de novo and inherited deletions and duplications at 
16p11.2 in individuals ascertained for diagnosis of autism spectrum disorder. J Med Genet. 
2010;47(3):195-203. 
18. Hogart A, Wu D, LaSalle JM, Schanen NC. The comorbidity of autism with the 
genomic disorders of chromosome 15q11.2-q13. Neurobiol Dis. 2010;38(2):181-91. 
19. Hiroi N, Takahashi T, Hishimoto A, Izumi T, Boku S, Hiramoto T. Copy number 
variation at 22q11.2: from rare variants to common mechanisms of developmental 
neuropsychiatric disorders. Mol Psychiatry. 2013. 
20. Woodbury-Smith M, Nicolson R, Zarrei M, Yuen RKC, Walker S, Howe J, et al. 
Variable phenotype expression in a family segregating microdeletions of the NRXN1 and 
MBD5 autism spectrum disorder susceptibility genes. NPJ Genom Med. 2017;2. 
21. Krumm N, Turner TN, Baker C, Vives L, Mohajeri K, Witherspoon K, et al. Excess 
of rare, inherited truncating mutations in autism. Nat Genet. 2015;47(6):582-8. 
 14 
22. O'Roak BJ, Stessman HA, Boyle EA, Witherspoon KT, Martin B, Lee C, et al. 
Recurrent de novo mutations implicate novel genes underlying simplex autism risk. Nat 
Commun. 2014;5:5595. 
23. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, et al. De 
novo mutations revealed by whole-exome sequencing are strongly associated with autism. 
Nature. 2012;485(7397):237-41. 
24. Yuen RK, Thiruvahindrapuram B, Merico D, Walker S, Tammimies K, Hoang N, et 
al. Whole-genome sequencing of quartet families with autism spectrum disorder. Nat Med. 
2015;21(2):185-91. 
25. Jiang YH, Yuen RK, Jin X, Wang M, Chen N, Wu X, et al. Detection of clinically 
relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am J 
Hum Genet. 2013;93(2):249-63. 
26. Ronemus M, Iossifov I, Levy D, Wigler M. The role of de novo mutations in the 
genetics of autism spectrum disorders. Nat Rev Genet. 2014;15(2):133-41. 
27. Kong A, Frigge ML, Masson G, Besenbacher S, Sulem P, Magnusson G, et al. Rate 
of de novo mutations and the importance of father's age to disease risk. Nature. 
2012;488(7412):471-5. 
28. Bolton P, MacDonald H, Pickles A, Rios P, Goode S, Crowson M, et al. A case-
control family history study of autism. Journal of Child Psychology & Psychiatry & Allied 
Disciplines. 1994;35(5):877-900. 
29. Piven J, Palmer P, Jacobi D, Childress D, Arndt S. Broader autism phenotype: 
evidence from a family history study of multiple-incidence autism families. Am J Psychiatry. 
1997;154(2):185-90. 
30. Folstein S, Rutter M. Infantile autism: a genetic study of 21 twin pairs. J Child 
Psychol Psychiatry. 1977;18(4):297-321. 
31. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic 
Heritability and Shared Environmental Factors Among Twin Pairs With Autism. Arch Gen 
Psychiatry. 2011;68(11):1095-102. 
32. Tick B, Bolton P, Happe F, Rutter M, Rijsdijk F. Heritability of autism spectrum 
disorders: a meta-analysis of twin studies. J Child Psychol Psychiatry. 2016;57(5):585-95. 
33. Ronald A, Happe F, Price TS, Baron-Cohen S, Plomin R. Phenotypic and genetic 
overlap between autistic traits at the extremes of the general population. J Am Acad Child 
Adolesc Psychiatry. 2006;45(10):1206-14. 
 15 
34. Robinson EB, St Pourcain B, Anttila V, Kosmicki JA, Bulik-Sullivan B, Grove J, et 
al. Genetic risk for autism spectrum disorders and neuropsychiatric variation in the general 
population. Nat Genet. 2016;48(5):552-5. 
35. Alarcon M, Cantor RM, Liu J, Gilliam TC, Geschwind DH, Autism Genetic Research 
Exchange C. Evidence for a language quantitative trait locus on chromosome 7q in multiplex 
autism families. Am J Hum Genet. 2002;70(1):60-71. 
36. Werling DM, Lowe JK, Luo R, Cantor RM, Geschwind DH. Replication of linkage at 
chromosome 20p13 and identification of suggestive sex-differential risk loci for autism 
spectrum disorder. Mol Autism. 2014;5(1):13. 
37. Woodbury-Smith M, Bilder DA, Morgan J, Jerominski L, Darlington T, Dyer T, et al. 
Combined genome-wide linkage and targeted association analysis of head circumference in 
autism spectrum disorder families. J Neurodev Disord. 2017;9:5. 
38. Coon H, Villalobos ME, Robison RJ, Camp NJ, Cannon DS, Allen-Brady K, et al. 
Genome-wide linkage using the Social Responsiveness Scale in Utah autism pedigrees. Mol 
Autism. 2010;1(1):8. 
39. Anney R, Klei L, Pinto D, Almeida J, Bacchelli E, Baird G, et al. Individual common 
variants exert weak effects on the risk for autism spectrum disorders. Hum Mol Genet. 
2012;21(21):4781-92. 
40. Anney R, Klei L, Pinto D, Regan R, Conroy J, Magalhaes TR, et al. A genome-wide 
scan for common alleles affecting risk for autism. Hum Mol Genet. 2010;19(20):4072-82. 
41. Wang K, Zhang H, Ma D, Bucan M, Glessner JT, Abrahams BS, et al. Common 
genetic variants on 5p14.1 associate with autism spectrum disorders. Nature. 
2009;459(7246):528-33. 
42. Autism Spectrum Disorders Working Group of The Psychiatric Genomics C. Meta-
analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a 
novel locus at 10q24.32 and a significant overlap with schizophrenia. Mol Autism. 2017;8:21. 
43. Grove J, Ripke S, Als TD, Mattheisen M, Walters R, Won H, et al. Common risk 
variants identified in autism spectrum disorder. bioRxiv. 2017. 
44. Weiner DJ, Wigdor EM, Ripke S, Walters RK, Kosmicki JA, Grove J, et al. 
Polygenic transmission disequilibrium confirms that common and rare variation act 
additively to create risk for autism spectrum disorders. Nat Genet. 2017;49(7):978-85. 
45. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and 
guidelines for the interpretation of sequence variants: a joint consensus recommendation of 
 16 
the American College of Medical Genetics and Genomics and the Association for Molecular 
Pathology. Genet Med. 2015;17(5):405-24. 
46. Jarvik GP, Browning BL. Consideration of Cosegregation in the Pathogenicity 
Classification of Genomic Variants. Am J Hum Genet. 2016;98(6):1077-81. 
47. Lowther C, Speevak M, Armour CM, Goh ES, Graham GE, Li C, et al. Molecular 
characterization of NRXN1 deletions from 19,263 clinical microarray cases identifies exons 
important for neurodevelopmental disease expression. Genet Med. 2017;19(1):53-61. 
48. Moreno-De-Luca A, Evans DW, Boomer KB, Hanson E, Bernier R, Goin-Kochel RP, 
et al. The role of parental cognitive, behavioral, and motor profiles in clinical variability in 
individuals with chromosome 16p11.2 deletions. JAMA Psychiatry. 2015;72(2):119-26. 
49. Bishop S, Farmer C, Hus Bal V, Robinson E, Sanders S, Havdahl A, et al. Phenotype-
genotype associatioons in the Simons Simplex Collection for autism spectrum disorder. 
European Neuropsychopharmacology. 2016;26(Supplement 2):S155. 
50. Merikangas AK, Segurado R, Heron EA, Anney RJ, Paterson AD, Cook EH, et al. 
The phenotypic manifestations of rare genic CNVs in autism spectrum disorder. Mol 
Psychiatry. 2015;20(11):1366-72. 
51. Ozonoff S, Young GS, Carter A, Messinger D, Yirmiya N, Zwaigenbaum L, et al. 
Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. 
Pediatrics. 2011;128(3):e488-95. 
52. Kirov G, Rees E, Walters JT, Escott-Price V, Georgieva L, Richards AL, et al. The 
penetrance of copy number variations for schizophrenia and developmental delay. Biol 
Psychiatry. 2014;75(5):378-85. 
53. Carter MT, Scherer SW. Autism spectrum disorder in the genetics clinic: a review. 
Clin Genet. 2013;83(5):399-407. 
54. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. 
Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for 
individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 
2010;86(5):749-64. 
55. Shen Y, Dies KA, Holm IA, Bridgemohan C, Sobeih MM, Caronna EB, et al. Clinical 
genetic testing for patients with autism spectrum disorders. Pediatrics. 2010;125(4):e727-35. 
56. Tammimies K, Marshall CR, Walker S, Kaur G, Thiruvahindrapuram B, Lionel AC, 
et al. Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome 
Sequencing in Children With Autism Spectrum Disorder. JAMA. 2015;314(9):895-903. 
 17 
57. Miles JH, Takahashi TN, Bagby S, Sahota PK, Vaslow DF, Wang CH, et al. Essential 
versus complex autism: definition of fundamental prognostic subtypes. Am J Med Genet A. 
2005;135(2):171-80. 
58. Geschwind DH, State MW. Gene hunting in autism spectrum disorder: on the path to 
precision medicine. Lancet Neurol. 2015;14(11):1109-20. 
59. Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From 
Polygenic to Omnigenic. Cell. 2017;169(7):1177-86. 
60. Sahin M, Sur M. Genes, circuits, and precision therapies for autism and related 
neurodevelopmental disorders. Science. 2015;350(6263). 
61. Mei Y, Monteiro P, Zhou Y, Kim JA, Gao X, Fu Z, et al. Adult restoration of Shank3 
expression rescues selective autistic-like phenotypes. Nature. 2016;530(7591):481-4. 
62. Silva AJ, Ehninger D. Adult reversal of cognitive phenotypes in neurodevelopmental 
disorders. J Neurodev Disord. 2009;1(2):150-7. 
63. Silverman JL, Smith DG, Rizzo SJ, Karras MN, Turner SM, Tolu SS, et al. Negative 
allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social 
deficits in mouse models of autism. Sci Transl Med. 2012;4(131):131ra51. 
64. Ghosh A, Michalon A, Lindemann L, Fontoura P, Santarelli L. Drug discovery for 
autism spectrum disorder: challenges and opportunities. Nat Rev Drug Discov. 
2013;12(10):777-90. 
 
 
 
 
 
 18 
Table 1: Example prevalences of rare CNVs in ASD and population samples 
 
 
Locus Freq. in ASD* % Freq. in population** % 
15q13.3del 0.002 0.002 
15q13.3dup 0 <0.0001 
16p11.2del 0.002 <0.0001 
16p11.2dup 0.002 <0.0001 
NRXN1 del 0.002 <0.0001 
SHANK3 del 0.002 NK 
* Frequency based on MSSNG 9  for ASD probands (N=1,739) and affected siblings (N=878). 
** Frequency based on UK Biobank samples (N=152,000).  
del=deletion; dup=duplication; nk=unknown 
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Legend 
 
Figure 1: Genotyping platforms with details of their resolution, the types of variants 
detected and example ASD loci that have been identified.  
 
 
Figure 2: Flow diagram of approach to genetics investigation and evaluation for individuals 
with ASD 
 
